Published in Clin Infect Dis on May 01, 1996
Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients (FENSY) | NCT02544685
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis (2012) 3.31
Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis (2000) 2.34
Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol (2002) 1.87
Macrophages in resistance to candidiasis. Microbiol Mol Biol Rev (1997) 1.74
Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. Infect Immun (2008) 1.26
Characterization of binding of Candida albicans to small intestinal mucin and its role in adherence to mucosal epithelial cells. Infect Immun (2000) 1.21
Two unlike cousins: Candida albicans and C. glabrata infection strategies. Cell Microbiol (2013) 1.19
Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev (1997) 1.16
Hosting infection: experimental models to assay Candida virulence. Int J Microbiol (2011) 1.14
Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob Agents Chemother (2005) 1.14
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother (2012) 1.11
Normal adaptation of Candida albicans to the murine gastrointestinal tract requires Efg1p-dependent regulation of metabolic and host defense genes. Eukaryot Cell (2012) 1.06
Variation in Candida albicans EFG1 expression enables host-dependent changes in colonizing fungal populations. MBio (2012) 1.06
Reactivity of (1→3)-β-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis (2011) 1.05
A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur J Clin Microbiol Infect Dis (2008) 1.04
Inhibition of hydrophobic protein-mediated Candida albicans attachment to endothelial cells during physiologic shear flow. Infect Immun (2001) 1.01
The Pathophysiology and Treatment of Candida Sepsis. Curr Infect Dis Rep (2002) 1.00
Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. Eur J Clin Microbiol Infect Dis (2007) 0.97
Defining the transcriptomic landscape of Candida glabrata by RNA-Seq. Nucleic Acids Res (2015) 0.97
Gastrointestinal colonization by Candida albicans mutant strains in antibiotic-treated mice. Clin Diagn Lab Immunol (2001) 0.96
Serological profiling of a Candida albicans protein microarray reveals permanent host-pathogen interplay and stage-specific responses during candidemia. PLoS Pathog (2010) 0.96
Efficacy of surface-generated nitric oxide against Candida albicans adhesion and biofilm formation. Biofouling (2010) 0.96
Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Chemother (2006) 0.93
Intestinal lesions associated with disseminated candidiasis in an experimental animal model. J Clin Microbiol (2000) 0.92
The epidemiology and diagnosis of invasive candidiasis among premature infants. Clin Perinatol (2014) 0.90
Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. Mayo Clin Proc (2010) 0.89
Synthetic analogues of beta-1,2 oligomannosides prevent intestinal colonization by the pathogenic yeast Candida albicans. Antimicrob Agents Chemother (2002) 0.88
Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge. PLoS Pathog (2008) 0.86
Non-serum-dependent chemotactic factors produced by Candida albicans stimulate chemotaxis by binding to the formyl peptide receptor on neutrophils and to an unknown receptor on macrophages. Infect Immun (1999) 0.85
Candida esophagitis complicated by an esophago-airway fistula: report of a case. Surg Today (2009) 0.83
Regulatory circuits that enable proliferation of the fungus Candida albicans in a mammalian host. PLoS Pathog (2013) 0.83
Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol (2010) 0.82
Complementary amplicon-based genomic approaches for the study of fungal communities in humans. PLoS One (2015) 0.81
Human serum inhibits adhesion and biofilm formation in Candida albicans. BMC Microbiol (2014) 0.81
Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study. Eur J Clin Microbiol Infect Dis (2016) 0.81
Integrin αXβ₂ is a leukocyte receptor for Candida albicans and is essential for protection against fungal infections. J Immunol (2012) 0.80
Organotypical tissue cultures from adult murine colon as an in vitro model of intestinal mucosa. Histochem Cell Biol (2008) 0.79
The Role of the Intestinal Tract As a Source for Transmission of Nosocomial Pathogens. Curr Infect Dis Rep (2004) 0.78
Effectiveness of bombesin and Saccharomyces boulardii against the translocation of Candida albicans in the digestive tract in immunosuppressed rats. Surg Today (2005) 0.78
Macrophage-mediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene. Infect Immun (2009) 0.77
Blunted dynamics of adenosine A2A receptors is associated with increased susceptibility to Candida albicans infection in the elderly. Oncotarget (2016) 0.75
Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer (2005) 0.75
Factors Influencing Non-albicans Candidemia: A Case-Case-Control Study. Mycopathologia (2017) 0.75
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother (1998) 4.95
Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother (1995) 4.92
Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev (1994) 3.58
Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood (1997) 3.45
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis (2005) 2.34
Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood (1995) 2.23
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis (1993) 2.03
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother (2001) 2.03
Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis (2001) 1.88
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant (2006) 1.85
Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol (1998) 1.55
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis (2001) 1.39
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant (2006) 1.35
Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J Clin Microbiol (1999) 1.32
Bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in patients with acute leukemia. Chest (1988) 1.31
A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med (1992) 1.21
Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice. Antimicrob Agents Chemother (1990) 1.20
Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infect Dis (1993) 1.19
Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother (1993) 1.18
Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum. Ann Intern Med (1994) 1.15
A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice. Infect Immun (1990) 1.12
Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med (1996) 1.11
Chronic systemic candidiasis. Eur J Clin Microbiol Infect Dis (1989) 1.09
Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother (1999) 1.07
Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia (1997) 1.07
Fungal infections in iatrogenically compromised hosts. Adv Intern Med (1998) 0.97
Trial design for mold-active agents: time to break the mold--aspergillosis in neutropenic adults. Clin Infect Dis (2007) 0.94
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis (1997) 0.94
Iron acquisition by Cryptococcus neoformans. J Med Vet Mycol (1995) 0.93
Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis (2014) 0.93
Rhinocerebral mucormycosis with internal carotid occlusion: report of two cases and review of the literature. Laryngoscope (1985) 0.93
Problems and controversies in the management of hematogenous candidiasis. Clin Infect Dis (1996) 0.91
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer (1994) 0.91
Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis (1997) 0.91
Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients. Bone Marrow Transplant (2006) 0.90
Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother (1998) 0.90
Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin Infect Dis (1994) 0.89
Investigation of an outbreak of gram-negative bacteremia among hematology-oncology outpatients. Infect Control Hosp Epidemiol (2000) 0.86
Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography. Antimicrob Agents Chemother (1995) 0.86
SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice. Antimicrob Agents Chemother (1995) 0.85
Cytokines as therapy for opportunistic fungal infections. Res Immunol (1998) 0.85
Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher (1995) 0.85
Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon-gamma and granulocyte-colony-stimulating factor. Transfusion (1995) 0.83
Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob Agents Chemother (1994) 0.82
Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis. Antimicrob Agents Chemother (1996) 0.82
Branhamella catarrhalis septicemia in patients with leukemia. Cancer (1988) 0.82
Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections. Antimicrob Agents Chemother (1995) 0.82
Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg (1997) 0.82
The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol (1998) 0.81
Predictors of outcome in cancer patients with candidemia. Ann Oncol (2000) 0.81
Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults. Leukemia (2002) 0.81
Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant (2004) 0.80
Update on invasive candidiasis. Adv Pharmacol (1997) 0.80
Malassezia and Trichosporon: two emerging pathogenic basidiomycetous yeast-like fungi. J Med Vet Mycol (1994) 0.80
Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia. Clin Infect Dis (1996) 0.79
The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis (1998) 0.79
Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans. Antimicrob Agents Chemother (1996) 0.79
Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy. Clin Infect Dis (2000) 0.79
Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients. Transpl Infect Dis (2013) 0.78
Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Clin Infect Dis (1995) 0.78
Activated lymphocytes reduce adherence of Aspergillus fumigatus. Med Mycol (1998) 0.77
Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med (1995) 0.77
gamma-Cyclodextrin:testosterone complex suitable for sublingual administration. J Pharm Sci (1987) 0.76
The clinical spectrum of stenotrophomonas (xanthomonas) maltophilia respiratory infection. Semin Respir Crit Care Med (2000) 0.76
Outpatient therapy for febrile neutropenia: who, when, and how? J Antimicrob Chemother (1999) 0.75
Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy. Clin Lab Haematol (1997) 0.75
Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins. Eur J Clin Microbiol Infect Dis (1991) 0.75
Fluconazole. J Med Vet Mycol (1992) 0.75
Acute fungal thyroiditis in a patient with acute myelogenous leukaemia. J Intern Med (1991) 0.75